Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The guanine nucleotide exchange factor VAV3 participates in ERBB4-mediated cancer cell migration

Autor: Ojala, Veera K., Knittle, Anna M., Kirjalainen, Peppi, Merilahti, Johannes A.M., Kortesoja, Maarit, Tvorogov, Denis, Vaparanta, Katri, Lin, Shujun, Kast, Jürgen, Pulliainen, Arto T., Kurppa, Kari J., Elenius, Klaus ^*

Publikováno v: In Journal of Biological Chemistry 14 August 2020 295(33):11559-11571

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations.

Autor: Chakroborty D; Institute of Biomedicine, University of Turku, Turku, Finland.; Medicity Research Laboratories, University of Turku, Turku, Finland.; Turku Doctoral Programme of Molecular Medicine, Turku, Finland.; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland., Ojala VK; Institute of Biomedicine, University of Turku, Turku, Finland.; Medicity Research Laboratories, University of Turku, Turku, Finland.; Turku Doctoral Programme of Molecular Medicine, Turku, Finland.; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland., Knittle AM; Institute of Biomedicine, University of Turku, Turku, Finland., Drexler J; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Tamirat MZ; Structural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University, Turku, Finland.; InFLAMES Research Flagship Center, Åbo Akademi University, Turku, Finland.; Graduate School of Åbo Akademi University (Informational and Structural Biology Doctoral Network), Turku, Finland., Ruzicka R; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Bosch K; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Woertl J; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Schmittner S; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Elo LL; Institute of Biomedicine, University of Turku, Turku, Finland.; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland., Johnson MS; Structural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University, Turku, Finland.; InFLAMES Research Flagship Center, Åbo Akademi University, Turku, Finland., Kurppa KJ; Institute of Biomedicine, University of Turku, Turku, Finland.; Medicity Research Laboratories, University of Turku, Turku, Finland.; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland., Solca F; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Elenius K; Institute of Biomedicine, University of Turku, Turku, Finland.; Medicity Research Laboratories, University of Turku, Turku, Finland.; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.; Department of Oncology, Turku University Hospital, Turku, Finland.

Publikováno v: Cancer research communications [Cancer Res Commun] 2022 Jan 07; Vol. 2 (1), pp. 10-27. Date of Electronic Publication: 2022 Jan 07 (Print Publication: 2022).